KIT and mastocytosis: In 2006, the FDA approved imatinib for adult patients with aggressive SM (ASM) without the D816V KIT mutation or with unknown or unavailable KIT mutational based on clinical data from single case reports and a small series of patients with mastocytosis treated with this drug [11].